Additionally, B7‐H3 has been shown to induce a hypoxic tumour microenvironment through aberrant angiogenesis, potentially leading to reduced chemotherapeutic agent delivery and consequently enhancing chemoresistance.13, 20. The gene discussed is CD276; the disease is neoplasm.